

UCSF

UC San Francisco Previously Published Works

Title

Systemic cytokines and GlycA discriminate disease status and predict corticosteroid response in HTLV-1-associated neuroinflammation.

Permalink

<https://escholarship.org/uc/item/6w72z08d>

Journal

Journal of neuroinflammation, 19(1)

ISSN

1742-2094

Authors

Assone, Tatiane

Menezes, Soraya Maria

de Toledo Gonçalves, Fernanda

et al.

Publication Date

2022-12-01

DOI

10.1186/s12974-022-02658-w

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

RESEARCH

Open Access



Systemic cytokines and GlycA discriminate disease status and predict corticosteroid response in HTLV-1-associated neuroinflammation

Tatiane Assone^{1,2,3}, Soraya Maria Menezes³, Fernanda de Toledo Gonçalves^{1,2}, Victor Angelo Folgosi^{1,2}, Gabriela da Silva Prates^{1,2}, Tim Dierckx³, Marcos Braz^{3,4}, Jerusa Smid⁵, Michel E. Haziot⁵, Rosa M. N. Marcusso⁵, Flávia E. Dahy⁵, Evelien Vanderlinden⁶, Sandra Claes⁶, Dominique Schols⁶, Roberta Bruhn^{7,8}, Edward L. Murphy^{7,8}, Augusto César Penalva de Oliveira⁵, Dirk Daelemans⁶, Jurgen Vercauteren³, Jorge Casseb^{1,2†} and Johan Van Weyenbergh^{3*†}

Abstract

Background: HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) is an incapacitating neuroinflammatory disorder for which no disease-modifying therapy is available, but corticosteroids provide some clinical benefit. Although HAM/TSP pathogenesis is not fully elucidated, older age, female sex and higher proviral load are established risk factors. We investigated systemic cytokines and a novel chronic inflammatory marker, GlycA, as possible biomarkers of immunopathogenesis and therapeutic response in HAM/TSP, and examined their interaction with established risk factors.

Patients and methods: We recruited 110 People living with HTLV-1 (PLHTLV-1, 67 asymptomatic individuals and 43 HAM/TSP patients) with a total of 946 person-years of clinical follow-up. Plasma cytokine levels (IL-2, IL-4, IL-6, IL-10, IL-17A, IFN- γ , TNF) and GlycA were quantified by Cytometric Bead Array and ¹NMR, respectively. Cytokine signaling and prednisolone response were validated in an independent cohort by nCounter digital transcriptomics. We used multivariable regression, machine learning algorithms and Bayesian network learning for biomarker identification.

Results: We found that systemic IL-6 was positively correlated with both age ($r = 0.50$, $p < 0.001$) and GlycA ($r = 0.45$, $p = 0.00049$) in asymptomatics, revealing an “inflammaging” signature which was absent in HAM/TSP. GlycA levels were higher in women ($p = 0.0069$), but cytokine levels did not differ between the sexes. IFN- γ ($p = 0.007$) and IL-17A ($p = 0.0001$) levels were increased in untreated HAM/TSP. Multivariable logistic regression identified IL-17A and proviral load as independent determinants of clinical status, resulting in modest accuracy of predicting HAM/TSP status (64.1%), while a machine learning-derived decision tree classified HAM/TSP patients with 90.7% accuracy.

[†]Jorge Casseb and Johan Van Weyenbergh are co-senior authors

*Correspondence: johan.vanweybergh@kuleuven.be; j.vw@live.be

³Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
Full list of author information is available at the end of the article



Pre-treatment GlycA and TNF levels significantly predicted clinical worsening (measured by Osame Motor Disability Scale), independent of proviral load. In addition, a poor prednisolone response was significantly correlated with higher post-treatment IFN- γ levels. Likewise, a transcriptomic IFN signaling score, significantly correlated with previously proposed HAM/TSP biomarkers (*CASP5/CXCL10/FCGR1A/STAT1*), was efficiently blunted by in vitro prednisolone treatment of PBMC from PLHTLV-1 and incident HAM/TSP.

Conclusions: An age-related increase in systemic IL-6/GlycA levels reveals inflammaging in PLHTLV-1, in the absence of neurological disease. IFN- γ and IL-17A are biomarkers of untreated HAM/TSP, while pre-treatment GlycA and TNF predict therapeutic response to prednisolone pulse therapy, paving the way for a precision medicine approach in HAM/TSP.

Keywords: HTLV-1, HAM/TSP, Cytokines, Inflammation, Corticosteroids

Introduction

Human T-cell Lymphotropic Virus type-1 (HTLV-1) is unique as it is both oncogenic [1, 2] and capable of triggering HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) and other inflammatory diseases [3–5]. Worldwide, 10 million people are estimated to be living with HTLV-1 (PLHTLV-1) [3], of which 1–2% develop HAM/TSP, an incapacitating, progressive neuroinflammatory disorder [4, 5].

Currently, no disease-modifying therapy is available for HAM/TSP but corticosteroids and other immunomodulators (IFN- α , methotrexate, cyclosporin) provide some clinical benefit [4–6]. Moreover, we recently demonstrated HAM/TSP is an independent predictor for early mortality among PLHTLV-1 [7]. As such, validated biomarkers to predict and/or monitor disease progression for PLHTLV-1 and therapeutic outcome in HAM/TSP patients are direly needed [8].

Acute inflammation is routinely measured by systemic cytokines, while glycoprotein acetylation (GlycA) represents a novel marker for chronic inflammation, which reliably predicts long-term outcomes of inflammatory and infectious diseases in patient cohorts or large prospective population studies [9–12]. Up to now, GlycA has not been explored in HTLV-1 infection or HAM/TSP. Lifelong chronic infection with other latent viruses (CMV and HIV) causes long-term activation of the immune system over time, contributing to inflammaging [13]. Although extensively described in people living with HIV-1 [14, 15], data on inflammaging are lacking in PLHTLV-1. Therefore, we investigated pro- and anti-inflammatory cytokines and GlycA as possible biomarkers of inflammaging, immunopathogenesis and therapeutic response in HAM/TSP, using unique samples from a large cohort of PLHTLV-1 with an exceptionally long clinical follow-up (range 2–20 years).

Patients and methods

Cohort characteristics, patient recruitment and sampling strategy

From an ongoing open cohort study researching the natural history of HTLV-1 infection [7], we selected all first available plasma samples (closest to recruitment into the cohort) from patients with definite HAM/TSP before treatment, as well as age- and gender-matched first available samples (closest to recruitment into the cohort) of PLHTLV-1 who were neurologically asymptomatic (AS) during clinical follow-up (study period: August 1997 to December 2019). All volunteers underwent serological screening for HTLV-1 at the “Emilio Ribas” Institute of Infectious Diseases, using GOLD ELISA HTLV-1/2 (Diasorin, UK), followed by confirmation with Western Blot (MP Diagnostics, HTLV Blot 2.4[®]) and in-house nested PCR [16]. Paired follow-up samples were obtained after methylprednisolone pulse therapy for 38 HAM/TSP patients (several cycles per patient, total duration ranged from 1.5 to 18.6 years). Blood samples were collected in K₃-EDTA (0.054 ml/tube), plasma was separated by centrifugation (15 min, 2500 rpm) and PBMC were purified by Ficoll density gradient centrifugation (GE Healthcare Life, USA). Cells were washed with saline solution, the cell number was adjusted to 10⁶ cells, followed by storage (as “dry pellet”) at – 80 °C. DNA was extracted using a commercial kit (Illustra Tissue and Cells Genomic Prep Mini Spin kit, Fairfield, CA) according to the manufacturer’s instructions, and stored at – 80 °C.

Quantification of HTLV-1 proviral load (PVL)

HTLV-1 proviral load was quantified by real-time PCR, using primers and probes targeting the HTLV-1 *pol* gene, with the human albumin gene as internal reference, as described previously [16]. All samples were analyzed in duplicate, and results expressed as HTLV-1 DNA copies/10⁶ PBMCs.

Neurological evaluation, HAM/TSP diagnosis and treatment

PLHTLV-1 were classified in two groups according to their neurological status: 67 asymptomatic HTLV-1-infected individuals and 43 HAM/TSP patients, of which 38 provided paired samples after treatment with methylprednisolone (1 g intravenously, every 45 days). HAM/TSP diagnostic criteria was based on recommendations from an international consortium [17]. Clinical evaluation and a standardized screening neurological examination were performed by a board-certified neurologist, blinded for HTLV-1 clinical status for all subjects. For clinical follow-up, the Osame Motor Disability Scale was used, ranging from 0 (no walking or running disabilities) to 13 (cannot even move toes). Methylprednisolone pulse therapy was offered to all HAM/TSP patients as first-line treatment, except for those with diabetes and/or urinary infection, the latter were excluded from this study.

Plasma cytokine levels

Concentrations of plasma (undiluted) cytokines were measured using the CBA (Cytometric Bead Array, BD Biosciences) Human Th1/Th2/Th17 Cytokine Kit, including Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-6 (IL-6), Interleukin-10 (IL-10), Tumor Necrosis Factor (TNF), Interferon- γ (IFN- γ), and Interleukin-17A (IL-17A), in accordance with the manufacturer's instructions.

Plasma CXCL10 levels

An additional biomarker, the chemokine CXCL10 (also known as IP-10) was quantified with the Bio-Plex Pro Human Chemokine IP-10/CXCL10 kit (Bio-Rad), following the manufacturer's instructions [18].

GlycA (glycoprotein acetyl) quantification in plasma

GlycA concentration was quantified using the Nightingale Health Ltd. high-throughput metabolomics platform (Helsinki, Finland), as previously described [9]. Briefly, a $^1\text{H-NMR}$ spectrum is taken from 350 μl of plasma, with the area under the peak measured at approximately 2 ppm quantifying signal originating from N-acetyl sugar groups present on acute phase glycoproteins (α -1-acid glycoprotein, α -1-antitrypsin, α -1-antichymotrypsin, haptoglobin, transferrin).

Data collection and quality control

Data entry in the electronic database RedCap [19] was performed by two administrative assistants, and subsequently checked by the first and last author.

Ethical issues

The Ethical Board of "Instituto de Infectologia Emilio Ribas", Sao Paulo-Brazil, approved the protocol (Number 07688818.2.1001.0061). Signed informed consent was obtained from all participants prior to study inclusion.

Digital transcriptomics and biological pathway analysis

Digital transcriptomic analysis (nCounter, Nanostring Technologies) and biological pathway analysis of *in vitro* prednisolone response was performed as previously described [20, 21], using the Myeloid/Innate Immunity Panel, consisting of >750 host genes, as well as customized HTLV-1 Hbz and Tax probes. Specific cytokine signaling scores were calculated as z-scores of the geometric mean of a set of curated transcripts (nSolver software) for each cytokine or cytokine family (IL-10, IFN, IL-17, IL4/IL-13, IL-2 family). PBMCs were obtained from an independent, previously characterized cohort of PLHTLV-1 (4 asymptomatic, 4 HAM/TSP patients), as well as age-, gender- and ethnicity-matched healthy controls ($n=4$) from the HOST study [22]. PBMCs were cultured in RPMI supplemented with 10% FCS, in the absence or presence of 10 $\mu\text{g/ml}$ of prednisolone (Sigma) for a short time period (36 h), as determined by our previous studies [21, 23–26].

Statistical analysis, machine learning and Bayesian network analysis

Statistical analysis was performed using XLStat and GraphPad Prism version 9, San Diego, CA). Logistic regression and non-parametric statistical tests (Mann–Whitney, Wilcoxon tests, Spearman correlation) were used, except for Maximal Osame Motor Disability Score (which followed normal distribution, ANOVA), with Bonferroni correction for multiple comparisons as indicated in the text. For prednisolone response *in vitro*, one sample t test was used to compare groups to the mean value of incident HAM/TSP, since numbers (4 in each group) were too small to apply generalized linear mixed models. Machine learning algorithms (attribute selection, J48 and PART decision trees) were applied using Weka (version 3.8.4). Bayesian network analysis was performed as previously described [27].

Results

Age and gender differentially affect cytokines and GlycA in people living with HTLV-1, independent of proviral load

As shown in Table 1, HAM/TSP patients were age- and gender-matched to HTLV-1-infected controls without neurological symptoms (asymptomatics, AS), while

Table 1 Principal characteristics of study participants (AS vs. HAM/TSP)

Variables	Asymptomatics (n = 67)	HAM/TSP (n = 43)	P value ^a
Gender n (%)			0.24
Male	20 (30.8)	14 (31.1)	
Female	47 (68.2)	29 (68.9)	
Age (years) in entry of cohort ^b			0.40
Median (± SD)	51 (13)	48 (13)	
Time Follow-up (years)			0.37
Median (± SD)	8.6 (5.7)	8.6 (3.7)	
Range (min–max)	1.5–20.8	1.5–18.6	
HTLV-1 Proviral Load ^c			0.0007
Median (95% CI)	3845 (839–18,953)	28,184 (14,464–53,864)	

^a Statistical tests: chi-square for categorical variables, Mann–Whitney test for numerical variables

^b Age missing for 1 HAM/TSP

^c HTLV-1 DNA copies/10⁶ PBMCs, proviral load missing for 10 AS and 4 HAM/TSP

proviral load was increased in HAM/TSP, as expected [4, 5]. Since age and gender are major determinants of HAM/TSP pathogenesis, as disease onset usually occurs after several decades and women are more affected [4, 5], we investigated if cytokines or GlycA were linked to these demographics, in the absence or presence of neuroinflammation. Biological sex did not influence systemic cytokine levels (data not shown), whereas both IL-6 (Spearman's $r=0.36$, $p=0.00018$) and IL-10 ($r=0.22$, $p=0.021$) were positively correlated with age in PLHTLV-1 (Fig. 1A–D). Surprisingly, this age-dependent cytokine increase was specific to AS ($r=0.50$, $p<0.0001$, Fig. 1B–E), and absent in HAM/TSP (Fig. 1C–F). In contrast, chronic inflammation marker GlycA did not correlate with age ($p=0.12$), but was higher in females ($p=0.0069$, Fig. 1G). Among all cytokines, only IL-6 was significantly correlated with GlycA in AS (Fig. 1H, $p=0.00049$, $r=0.45$) but not HAM/TSP patients ($p=0.16$), revealing an “inflammaging” signature which was surprisingly limited to PLHTLV-1 without neuro-inflammatory disease. Correlations of IL-6 with age and with GlycA remained significant after Bonferroni correction for multiple testing, while IL-10 correlation with age was not. Of note, none of the cytokines nor GlycA were significantly correlated with proviral load (Fig. 1I and not


shown), but a tendency was observed for IFN- γ (Fig. 1I, $r=0.20$, $p=0.054$).

Pro-inflammatory cytokines IFN- γ and IL-17A are biomarkers of untreated HAM/TSP

When comparing cytokine levels between clinical groups, we observed a significant increase in IFN- γ ($p=0.007$) and IL-17A ($p=0.0001$) in HAM/TSP patients, as compared to AS, while other cytokines and GlycA did not differ (Fig. 2). Using logistic regression (detailed in Additional file 1: Table S1), we found that IL-17A and proviral load were independently associated with clinical status, consistent with a weak correlation between IFN- γ and proviral load (Fig. 1I). However, logistic regression resulted in low classification accuracy for HAM/TSP patients, as only 25/39 (64.1%) were correctly classified, in contrast to 49/57 (86.0%) of correctly predicted AS (ROC AUC 0.85). Therefore, we used machine learning algorithms to improve classification, which revealed a decision tree (Fig. 3A) classifying 39/43 HAM/TSP and 58/67 AS, respectively, with 90.7% and 86.6% accuracy (ROC AUC 0.87). Among the first branches in this decision tree are IL-17A and IL-10, confirming previous findings in a UK cohort [28].

(See figure on next page.)

Fig. 1 Age and gender differentially affect cytokines and chronic inflammation marker GlycA in people living with HTLV-1, independent of proviral load. **A** IL-6 levels are significantly correlated with age at sampling in all PLHTLV-1, driven by the strong correlation in asymptomatic individuals (AS) (**B**), which is absent in HAM/TSP patients (**C**). **D** IL-10 levels are significantly correlated with age at sampling in all PLHTLV-1, driven by the strong correlation in AS (**E**), which is absent in HAM/TSP patients (**F**). **G** GlycA levels are significantly higher in female PLHTLV-1 ($p=0.0069$, Mann–Whitney test). **H** GlycA levels are positively correlated with IL-6 levels in AS only ($p=0.00049$, $r=0.45$). **I** Proviral load is not significantly correlated with IL-6 ($p=0.07$, $p=0.45$) or GlycA levels ($p=-0.06$, $p=0.72$) in PLHTLV-1, while a tendency is observed for IFN- γ ($p=0.20$, $p=0.054$). Correlation is determined using Spearman's method, uncorrected p values are reported, significant correlations of IL-6 with age and with GlycA were robust to correction for multiple testing (Bonferroni $p<0.05$)







Fig. 2 HAM/TSP disease status is characterized by increased IFN-γ and IL-17A. Among all cytokines tested, only IFN-γ ($p = 0.0054$) and IL-17A ($p < 0.0001$) levels in HAM/TSP patients ($n = 43$) were significantly different (Mann-Whitney test), as compared to asymptomatic individuals (AS, $n = 67$), both associations were robust to correction for multiple testing (Bonferroni $p < 0.05$)



Bayesian networks are graphical models that are widely used in systems biology to depict genes/proteins as nodes and connections between genes as edges, based on both linear and non-linear associations between the nodes. Thus, network connections in Bayesian networks have been demonstrated to accurately capture the functional and mechanistic relationship of genes/proteins that can inform on disease mechanisms and help define composite sets of molecular markers [29–31]. Therefore, we used Bayesian network learning to identify direct vs. indirect associations between cytokines, GlycA, clinical and demographic data, similar to previous analysis in HTLV-1-associated leukemia [27]. As shown in Fig. 3B, only IL-17A was directly connected to clinical status, while all other cytokines were ‘upstream’ of IL-17A. This Bayesian network revealed a direct link between GlycA and IL-6, whereas the observed correlation between age and IL-6 (Fig. 1A, B) appears dependent on TNF and IFN- γ , the latter directly influencing GlycA. IFN- γ was found upstream of all other cytokines and, consequently, of disease status, which underscores the previously identified IFN gene signature in HAM/TSP [32]. Of interest, in this unsupervised model, proviral load was not significantly associated with the other parameters and hence absent from the network.

Systemic cytokines and GlycA are biomarkers of corticosteroid therapeutic response in HAM/TSP

Next, we investigated if cytokines and GlycA might be candidate biomarkers for therapeutic response in HAM/TSP patients. In this cohort, all eligible patients were uniformly treated with intravenous methylprednisolone pulse therapy, which allowed unbiased comparisons before and after treatment. Patients with >1 year pulse therapy follow-up were classified as responders ($n=13$) and non-responders ($n=25$), based on changes in Osame Motor Disability Score (decrease or ≤ 1 : responders, increase >1: non-responders). All patients significantly decreased IL-17A levels after treatment (Fig. 4A, $p=0.003$, Wilcoxon test), while strong variability but no directionality was observed for any other cytokine. However, lower IFN- γ levels after treatment were correlated with better clinical response to corticosteroid pulse therapy (Fig. 4B, $p=0.010$). In addition,


pre-treatment TNF levels were significantly associated with therapeutic outcome (Fig. 4B, $p=0.011$). In contrast to all cytokines, GlycA levels were significantly increased (Fig. 4C left panel, $p=0.0087$, Wilcoxon test). Moreover, pre-treatment GlycA levels were able to predict therapeutic response, (measured by quantitative changes in Osame Motor Disability Score), either by itself (Fig. 4C, left panel) or as a combined TNF/GlycA score (Fig. 4C, right panel). Multivariate linear regression (Additional file 1: Table S2) confirmed both TNF and GlycA as independent predictors of disability progression, while age, gender and proviral load were not. Since disability progression was measured over a long period of time (range 1.5–18.6 years), including several cycles of pulse therapy for most patients, therapeutic response to corticosteroids cannot be unequivocally distinguished from the natural history of HAM/TSP, i.e., disease progression over time. Therefore, we calculated disease progression rate for both pulse time and total time of follow-up, as well as disease duration (time since onset of neurological symptoms). As shown in Additional file 1: Fig. S1A, only disease progression rate calculated as δ Osame (quantitative changes in Osame Motor Disability Score) over total pulse time, but not over time of follow-up at sampling, was significantly correlated with pre-treatment GlycA levels ($r=0.42$, $p=0.024$, $n=29$). Neither maximal disease progression over the total disease duration (Additional file 1: Fig. S1A), nor age of onset or age at entry in the cohort were significantly correlated with GlycA levels (Additional file 1: Fig. S1B) or TNF levels (data not shown). In addition, low vs. high GlycA levels before treatment significantly discriminated between low vs. high disease progression rate (δ Osame/pulse time, Additional file 1: Fig. S1C, $p=0.021$, Mann–Whitney test), while TNF levels did not. This finding, in addition to GlycA’s relative stability over time (Fig. 4C and [9–11]), underscores the potential of GlycA as a novel and clinically useful biomarker for corticosteroid response in HAM/TSP.

Transcriptomic validation of cytokine signatures in PLHTLV-1 and incident HAM/TSP

To confirm and extend our findings of cytokine signatures at the protein level (Figs. 1, 2, 3 and 4), we used digital transcriptomics (nCounter) to provide broader

(See figure on next page.)

Fig. 4 Cytokines and GlycA predict therapeutic success vs. failure of methylprednisolone pulse therapy in HAM/TSP patients. **A** Among all plasma cytokines measured in HAM/TSP patients, only IL-17A significantly decreases after pulse therapy with intravenous methylprednisolone (Wilcoxon test $p=0.003$, Bonferroni correction $p<0.05$). **B** Pre-treatment TNF (left panel) and post-treatment IFN- γ (right panel) are correlated with the magnitude of clinical worsening after methylprednisolone pulse therapy (Spearman correlation), measured as quantitative changes in Osame Motor Disability Score. **C** GlycA levels are significantly increased after methylprednisolone pulse therapy ($p=0.0087$, Wilcoxon test, left panel). Pre-treatment GlycA levels are correlated with the magnitude of clinical worsening after methylprednisolone pulse therapy (Spearman correlation, middle panel). A higher TNF/GlycA score ($0.025 \times \text{TNF} + 9.18 \times \text{GlycA} - 7.28$) predicts worse Osame Motor Disability Score after methylprednisolone pulse therapy (right panel, ANOVA with Bonferroni post-test, $*p=0.010$)



mechanistic insight into the downstream cytokine signaling pathways [20, 21] mediating HAM/TSP disease progression, and the effect of prednisolone treatment in vitro. From a well-characterized US cohort of PLHTLV-1 [22], we selected 4 AS and 4 HAM/TSP patients (including the only two incident HAM/TSP cases from the entire HTLV-1 cohort), and age-, gender- and ethnicity-matched healthy controls ($n=4$). First, we confirm that exacerbated IFN signaling is a hallmark of HAM/TSP disease status [32], being significantly higher in incident HAM/TSP (Fig. 5A), as compared to healthy controls (fivefold, $p=0.022$) and AS (fourfold $p=0.0085$), when quantified ex vivo by nCounter. Likewise, ex vivo IL-17 signaling score was also increased in incident HAM/TSP (Fig. 5B), as compared to healthy controls (twofold, $p=0.044$) and AS (1.5-fold, $p=0.14$). Similar to our findings in HAM/TSP patients from the Brazilian cohort, IFN signaling (3.5-fold, $p=0.0096$) and IL-17 signaling score (twofold, $p=0.089$) were downregulated in the US cohort at (4-year) follow-up. However, no uniform HAM/TSP treatment protocol exists for the US HOST cohort, and the number of patients was too small to correlate cytokine signaling in vitro to therapeutic response or disability score.

Nevertheless, IFN signaling (measured by nCounter) was effectively and homogeneously down-regulated in all clinical groups by in vitro prednisolone treatment (Fig. 5C), which was further confirmed by decreased expression of the IFN- γ -regulated MHC Class II antigen presentation pathway (Fig. 5C). In contrast, in vitro prednisolone treatment did not have a uniform effect on IL-10 signaling, IL4/IL-13 signaling, IL-17 signaling or IL-2 cytokine family signaling (data not shown) but was strongly variable among the four clinical groups. Finally, we investigated if nCounter IFN signaling score was correlated with previously identified HAM/TSP transcriptomic biomarkers (*CASP5*, *FCGR1A*, *STAT1* identified in [32]) and *CXCL10*, proposed by several groups [4, 5, 8, 33] as a sensitive biomarker for HAM/TSP disease status and corticosteroid response. As shown in Fig. 5D, ex vivo *CASP5*, *CXCL10*, *FCGR1A* and *STAT1* transcript

levels were significantly (all $p<0.05$ with Bonferroni correction) correlated with IFN signaling score. In contrast, HTLV-1 transcripts *Hbz* and *Tax* were not significantly correlated with IFN signaling score (Fig. 5D), suggesting that different cytokine signatures in PLHTLV-1 and HAM/TSP patients are not directly triggered by retroviral transcription.

Discussion

In this observational study, we selected 110 biobanked plasma samples, corresponding to all first available samples, i.e., closest to the date of entry in a large open cohort of PLHTLV-1, corresponding to a total of 946 person-years of clinical follow-up, including 43 HAM/TSP patients and 67 asymptomatic PLHTLV-1. Using these unique samples, we demonstrated systemic cytokines and GlycA as candidate biomarkers of inflammaging, immunopathogenesis and therapeutic response in HAM/TSP.

Inflammaging has been extensively documented in people living with HIV-1 [14, 15], but this is the first report of inflammaging in PLHTLV-1, characterized by an age-dependent increase in pro-inflammatory cytokine IL-6, which was positively correlated with chronic inflammation marker GlycA (Fig. 1). Among pro-inflammatory cytokines, IL-6 uniquely predicts global functional decline in aging [34] and inflammaging in a systematic review and meta-analysis [35]. With 110 PLHTLV-1 in our study, we had sufficient statistical power for a subgroup analysis. The significant (Bonferroni-corrected) correlation between age and systemic IL-6 levels in AS agrees with the extensively documented positive correlation in the general population. For instance, a recent study [18], described effect sizes for the correlation between age and IL-6 in two large Japanese cohorts ($\rho=0.44$, $n=684$ and $\rho=0.60$, $n=841$) that were very similar to ours ($\rho=0.50$, $n=67$ AS). On the other hand, the absence of correlation between pro-inflammatory IL-6 and age in HAM/TSP patients is a surprising new finding in (neuro)inflammatory disease, further strengthened by the absence of correlation between IL-6

(See figure on next page.)

Fig. 5 Transcriptomic validation of cytokine signaling pathways and prednisolone response in an independent cohort of PLHTLV-1. Digital transcriptomics (nCounter) was used to quantify cytokine signaling pathways in HAM/TSP disease progression, and the effect of in vitro prednisolone treatment in PBMCs from four AS, four HAM/TSP patients (including the two only incident HAM/TSP in the HOST cohort), and four age-, gender- and ethnicity-matched healthy controls. **A** Ex vivo IFN signaling score was significantly higher in incident HAM/TSP as compared to healthy controls, AS, and HAM/TSP at 4-year follow-up (one sample t test). **B** Ex vivo IL-17 signaling score was significantly higher in incident HAM/TSP as compared to healthy controls and tends to decline in HAM/TSP at 4-year follow-up (one sample t test). **C** IFN signaling was homogeneously down-regulated in all clinical groups by prednisolone treatment in vitro (left panel, Wilcoxon test $p<0.0001$). Down-regulation was confirmed by decreased expression of the IFN- γ -regulated MHC Class II antigen presentation pathway (right panel, Wilcoxon test $p<0.001$). **D** Ex vivo transcriptomic IFN signaling score measured by nCounter is significantly correlated with mRNA levels of previously identified HAM/TSP biomarkers *CASP5*, *FCGR1A*, *STAT1*, and *CXCL10* (all $p<0.05$ with Bonferroni correction), but not to HTLV-1 mRNAs *Hbz* and *Tax*. HC: healthy controls (open circles); AS asymptomatics (black circles), *iHAM* incident HAM/TSP (orange circles), HAM/TSP at 4-year follow-up (red circles), *Con* untreated in vitro PBMCs, *Pred* prednisolone-treated PBMCs in vitro. Paired samples from *iHAM* patients at diagnosis and at follow-up are identified by dashed lines.




Fig. 5 (See legend on previous page.)

and GlycA in HAM/TSP patients only. Again, the significant correlation between IL-6 and GlycA we observed in AS is similar to previous findings in a large populational study [10]. Moreover, both instances of loss of correlation in HAM/TSP patients were observed in pre-treatment samples, hence not biased by pharmacological intervention and likely to reflect an early feature of HAM/TSP pathogenesis.

Although IL-10 was weakly correlated with age in asymptomatics, the IL6/IL10 ratio, representing a higher pro-inflammatory state, significantly increases with age ($\pm 50\%/15$ years, $p=0.014$), and also corroborates the increased mortality rate observed in this cohort [7], as well as in a recent systematic review and meta-analysis of HTLV-1 adverse health outcomes [36]. Of note, in addition to its widely documented anti-inflammatory role, IL-10 might also exert pro-inflammatory functions, especially in the context of type I IFN, as reviewed by Mühl [37]. Since the IL6/IL10 ratio has been demonstrated as a sensitive biomarker of COVID-19 outcome [38], aging PLHTLV-1 might be at increased risk of developing severe or critical COVID-19. Of interest, this hypothesis was also supported by *in silico* findings [39]. Furthermore, we have previously described an age-dependent decrease of B cells in HAM/TSP patients [26], which might also lead to decreased SARS-CoV-2 vaccine-induced antibody response. Both hypotheses obviously remain to be confirmed in large observational studies, which are challenging in neglected diseases [40].

Regarding disease status, we have used complimentary analytical approaches, namely, multivariable regression, machine learning-derived decision trees and Bayesian network learning to model cytokine and GlycA interactions with demographic and clinical parameters. While multivariable logistic regression identified IL-17A and proviral load as independent predictors of HAM/TSP disease status, Bayesian network analysis enables visualization of the co-dependencies between cytokines in PLHTLV-1, and their associations with GlycA and disease status. Thus, we found that IL-17A appears intrinsically related to disease status in all three analytical models (regression, decision tree and Bayesian network). However, IFN- γ appears “upstream” of all other cytokines in the Bayesian network, which corroborates previous transcriptomic findings [32]. This study confirms the findings of Kagdi et al. for IFN- γ and IL-17A as biomarkers of untreated HAM/TSP [28]. In spite of our larger cohort (67 AS, 43 HAM/TSP), we did not observe increased IL-2 nor IL-10 in HAM/TSP, in contrast to Kagdi et al. (17 AS, 28 HAM/TSP). However, our decision tree (Fig. 3A) identified by Machine Learning is quite similar to the decision tree proposed by Kagdi et al. to classify AS, HAM/TSP and ATL patients based

upon IL-10 and IL-17 levels. Exacerbated IFN- γ production has been consistently demonstrated by numerous groups, either *ex vivo* (in serum/plasma) or *in vitro* (in supernatants of PBMCs cultured for 1–4 days), as a hallmark of HAM/TSP [4, 5, 28, 41–45]. Other pro- and anti-inflammatory cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, TNF) have yielded strongly diverging results between different groups regarding their up- or down-regulation in HAM/TSP vs. AS [28, 41–48]. This is most likely due to smaller cohort sizes, in addition to the choice of plasma/serum vs. cell culture supernatants or intracellular flow cytometry. In addition, differences in age, gender, genetics as well as the inclusion of treated HAM/TSP patients in some cohorts might also explain the observed discrepancies. Indeed, we found that IFN- γ and IL-17A are differentially impacted by corticosteroid pulse therapy: post-treatment IFN- γ levels are low in responders, while IL-17A levels decrease uniformly for all patients. Current clinical guidelines for HAM/TSP suggest that early HAM/TSP patients might benefit most from corticosteroid therapy [6], which is also supported the recent (and first placebo-controlled) randomized clinical trial for corticosteroid therapy in HAM/TSP (HAMLET-P [33]).

In addition to IL-17A, we found proviral load is an independent biomarker of untreated disease in HAM/TSP patients, consenting with the literature [4–7]. However, proviral load did not predict incident HAM/TSP cases in three out of four published Brazilian cohort studies [49–52]. Of those, only Tanajura et al. demonstrated proviral load as a significant predictor of neurological symptoms, but not definite HAM/TSP, during clinical follow-up [50]. Similar to Yamauchi et al. [8], we found that proviral load is not a biomarker for therapeutic response in HAM/TSP. However, we identified, for the first time, TNF and GlycA as independent predictors of clinical worsening, as measured by increased Osame Motor Disability Scale. To put this prediction into a patient-centered clinical context, the median Osame Motor Disability Scale of 4 in the low TNF/GlycA group corresponds to “needs a handrail when climbing stairs”, whereas the median of 8 in the high TNF/GlycA group corresponds to “can walk 1-5 m with bilateral support”. Notably, the high TNF/GlycA group also comprised the only fatal case among 43 HAM/TSP patients, with death related to HAM/TSP as described in our previous study [7]. Several other non-cytokine biomarkers, such as CXCL10 (also known as IP-10), Neurofilament Light Chain (NFL), and Chitotriosidase-1 (encoded by the *CHIT1* gene) have recently been proposed as biomarkers for HAM/TSP disease progression [4, 5, 8, 33, 53–58]. Although most inflammatory biomarkers correlate reasonably well between plasma and CSF [53–59], most of these published studies have focused on CSF samples for

the quantification of these biomarkers, which was neither logistically nor ethically possible in our cohort. Moreover, our goal was to define biomarkers that can be easily implemented in clinical practice, such as non-invasive plasma/serum samples, which also allow repeated testing before and after treatment at regular intervals. Thus, we quantified plasma CXCL10 protein levels by BioPlex immunoassay in 41 individuals from the São Paulo cohort (41 out of 110 PLHIV-1 with sufficient samples). We found that CXCL10 plasma levels did not differ significantly between AS (median 37,164 pg/ml, IQR [16,946–69,585], $n=26$) and HAM/TSP patients (before treatment, median 38,631, IQR [19,465–69,723], $n=15$). In addition, CXCL10 levels did not significantly correlate to age at sampling, sex or proviral load (all $p>0.05$, not shown). CXCL10 plasma levels also did not correlate to disease duration, disease severity (Osame Motor Scale), age of onset or therapeutic response to methylprednisolone pulse therapy (all $p>0.05$, not shown). However, these results should be interpreted with caution, due to the low number of HAM/TSP patients in this subset analysis. Finally, CXCL10 plasma levels were not significantly correlated with GlycA levels, neither with any of the 7 plasma cytokines (after Bonferroni correction).

Notable strengths and limitations of this study merit further detail. First, this study has a relatively large sample size, to our knowledge the largest yet with regard to plasma cytokines as candidate biomarkers in PLHIV-1 and HAM/TSP. Second, complete neurological evaluations of PLHIV-1 and uniform treatment strategy for HAM/TSP patients are major strengths, as well as a remarkably long follow-up (median 8.6 years in Brazil cohort, > 14 years in US cohort). A major limitation is the low incidence in the US cohort (2/2100 person-years), thus limiting our statistical power for replication. Other limitations include the lack of simultaneous protein (plasma/serum, CSF) and RNA (PBMC, CSF) quantification in both cohorts due to sample unavailability, as well as potential selection biases regarding patient recruitment and loss to follow-up [7], which are inherent to cohort studies in neglected diseases.

Conclusions

We found that the untreated disease status in HAM/TSP patients, as compared to age- and gender-matched asymptomatic PLHIV-1, is characterized by increased systemic IFN- γ and IL-17A. From a clinical point of view, plasma GlycA, IL-6, TNF and IFN- γ are promising candidate biomarkers for immunomonitoring of inflammation in PLHIV-1, and of disease progression and corticosteroid therapeutic response in HAM/TSP patients, respectively. In addition, we provide predictive

regression models and decision trees for prospective testing in clinical trials or independent cohort studies.

Abbreviations

AS: Asymptomatics; HAM/TSP: HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis; HIV: Human immunodeficiency virus; HTLV: Human T-cell leukemia virus; IFN: Interferon; IL: Interleukin; PLHIV-1: People living with HTLV-1; TNF: Tumor Necrosis Factor.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12974-022-02658-w>.

Additional file 1: Table S1. Multivariable logistic regression (Asymptomatics (AS) vs. HAM/TSP patients). **Table S2.** Multivariable linear regression of disease progression (measured by Osame Motor Disability Scale) in HAM/TSP patients. **Fig S1.** GlycA pre-treatment levels predict disease progression rate under prednisolone pulse therapy, independent of age at onset or disease duration.

Acknowledgements

The authors would like to thank all interns of the IIER Neurology program, and all persons living with HTLV-1 for their participation.

Author contributions

TA, SMM, MB, TD, EV, SC and JWV performed experiments and analyzed data. FTG, VA, GSP, JS, MEH, RMNM, FED, RB, EM, ACPO and JC provided patient samples and clinical data. JV, DS and DD participated in cytokine and statistical analysis. TA, JC and JWV wrote the main manuscript text and JWV prepared Figs. 1, 2, 3 and 4. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Funding

This research was funded by FAPESP Grant Numbers 2017/08320-5, 2018/07239-2 and 2016/03025-2 (scholarship to TA); CNPq (Scholarship to JC), FFM (support to JC), FWO (Grant G0A0621N to JWV) and KU Leuven ("Vaast Leysen Leerstoel voor Infectieziekten in Ontwikkelingslanden" to JWV). Specimen acquisition for the HTLV Outcomes Study was funded by a grant (R01-HL-62235) from the U.S. National Heart, Lung and Blood Institute (NHLBI).

Availability of data and materials

All data contained in the manuscript are available from the corresponding authors.

Declarations

Ethics approval and consent to participate

The Ethical Board of "Instituto de Infectologia Emilio Ribas", Sao Paulo-Brazil, approved the protocol (Number 07688818.2.1001.0061). Signed informed consent was obtained from all participants prior to study inclusion.

Consent for publication

All authors have seen and approved the manuscript and agree to its publication.

Competing interests

All authors declare no conflict of interest.

Author details

¹Laboratory of Medical Investigation LIM 56, Division of Dermatology and Institute of Tropical Medicine of Sao Paulo, Medical School, University of São Paulo, São Paulo, SP, Brazil. ²Laboratory of Immunohematology and Forensic Hematology-LIM40, Department of Forensic Medicine, Medical Ethics, Social Medicine and Work, University of São Paulo Medical School, São Paulo, Brazil. ³Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical

Research, KU Leuven, Leuven, Belgium. ⁴Programa de Pós-Graduação em Ciências da Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, Bahia, Brazil. ⁵Institute of Infectious Diseases “Emílio Ribas” (IIER) de São Paulo, São Paulo, SP, Brazil. ⁶Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. ⁷Vitalant Research Institute, San Francisco, CA, USA. ⁸University of California San Francisco, San Francisco, CA, USA.

Received: 14 February 2022 Accepted: 28 November 2022

Published online: 08 December 2022

References

- Tagaya Y, Gallo RC. The exceptional oncogenicity of HTLV-1. *Front Microbiol.* 2017;8:1425.
- Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia. *Nature.* 1981;294:268–71.
- Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. *Front Microbiol.* 2012;3:388.
- Bangham CRM, Araujo A, Yamano Y, Taylor GP. HTLV-1-associated myelopathy/tropical spastic paraparesis. *Nat Rev Dis Primer.* 2015;1:15012.
- Nozuma S, Jacobson S. Neuroimmunology of human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis. *Front Microbiol.* 2019;10:885.
- Araujo A, Bangham CRM, Casseb J, Gotuzzo E, Jacobson S, Martin F, Oliveira AP, on behalf of the International Retrovirology Association, et al. Management of HAM/TSP Systematic review and consensus-based recommendations 2019. *Neurol Clin Pract.* 2021;11(1):49–56. <https://doi.org/10.1212/CPJ.0000000000000832>.
- Marcusso RMN, Van Weyenbergh J, de Moura JVL, Dahy FE, de Moura Brasil Matos A, Haziot MEJ, et al. Dichotomy in fatal outcomes in a large cohort of people living with HTLV-1 in São Paulo, Brazil. *Pathogens.* 2019. <https://doi.org/10.3390/pathogens9010025>.
- Yamauchi J, Araya N, Yagishita N, Sato T, Yamano Y. An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers. *Pharmacol Ther.* 2021;218: 107669.
- Dierckx T, Verstockt P, Vermeire S, Van Weyenbergh J. GlycA, a nuclear magnetic resonance spectroscopy measure for protein glycosylation, is a viable biomarker for disease activity in IBD. *J Crohns Colitis.* 2019;13:389–94.
- Ritchie SC, Würtz P, Nath AP, Abraham G, Havulinna AS, Fearnley LG, et al. The biomarker GlycA is associated with chronic inflammation and predicts long-term risk of severe infection. *Cell Syst.* 2015;1:293–301.
- Dierckx T, Chiche L, Daniel L, Lauwerys B, Weyenbergh JV, Jourde-Chiche N. Serum GlycA level is elevated in active systemic lupus erythematosus and correlates to disease activity and lupus nephritis severity. *J Clin Med.* 2020;9(4):970.
- Lawler PR, Akinkuolie AO, Chandler PD, Moorthy MV, Vandenberg MJ, Schaumberg DA, Lee IM, Glynn RJ, Ridker PM, Buring JE, Mora S. Circulating N-linked glycoprotein acetyls and longitudinal mortality risk. *Circ Res.* 2016;118(7):1106–15.
- Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann N Y Acad Sci.* 2000;908:244–54.
- Babu H, Ambikan AT, Gabriel EE, SvenssonAkusjärvi S, Palaniappan AN, Sundaraj V, Mupanni NR, Sperk M, Cheedarla N, Sridhar R, Tripathy SP, Nowak P, Hanna LE, Neogi U. Systemic inflammation and the increased risk of inflamm-aging and age-associated diseases in people living with HIV on long term suppressive antiretroviral therapy. *Front Immunol.* 2019;27(10):1965.
- Sieg SF, Shive CL, Panigrahi S, Freeman ML. Probing the Interface of HIV and Inflammaging. *Curr HIV/AIDS Rep.* 2021;18(3):198–210.
- Montanheiro PA, Montanheiro PA, de Oliveira ACP, Posada-Vergara MP, Milagres AC, Tauil C, et al. Human T-cell lymphotropic virus type I (HTLV-1) proviral DNA viral load among asymptomatic patients and patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. *Braz J Med Biol Res.* 2005;38:1643–7.
- De Castro-Costa CM, Araújo AQC, Barreto MM, Takayanagui OM, Sohler MP, da Silva ELM, et al. Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). *AIDS Res Hum Retroviruses.* 2006;22:931–5.
- Van Loon E, Lamarthée B, Barba T, Claes S, Coemans M, de Looor H, Emonds MP, Koshiy P, Kuypers D, Proost P, Senev A, Sprangers B, Tinel C, Thauinat O, Van Craenenbroeck AH, Schols D, Naesens M. Circulating donor-specific anti-HLA antibodies associate with immune activation independent of kidney transplant histopathological findings. *Front Immunol.* 2022;23(13): 818569.
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009;42:377–81.
- Fukutani KF, Nascimento-Carvalho CM, Bouzas ML, Oliveira JR, Barral A, Dierckx T, et al. In situ immune signatures and microbial load at the nasopharyngeal interface in children with acute respiratory infection. *Front Microbiol.* 2018;9:2475.
- Moens B, Pannecouque C, López G, Talledo M, Gotuzzo E, Khouri R, Bitencourt A, Farré L, Galvão-Castro B, Vandamme AM, Van Weyenbergh J. Simultaneous RNA quantification of human and retroviral genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines. *Virology.* 2012;23(9):171.
- Kwaan N, Lee T-H, Chafets DM, Nass C, Newman B, Smith J, et al. Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data. *J Infect Dis.* 2006;194:1557–64.
- Menezes SM, Leal FE, Dierckx T, Khouri R, Decanine D, Silva-Santos G, Schnitman SV, Kruschewsky R, López G, Alvarez C, Talledo M, Gotuzzo E, Nixon DF, Vercauteren J, Brassat D, Liblau R, Vandamme AM, Galvão-Castro B, Van Weyenbergh J. A Fas^{hi} lymphoproliferative phenotype reveals non-apoptotic fas signaling in HTLV-1-associated neuroinflammation. *Front Immunol.* 2017;14(8):97.
- Moens B, Decanine D, Menezes SM, Khouri R, Silva-Santos G, Lopez G, Alvarez C, Talledo M, Gotuzzo E, de Almeida KR, Galvão-Castro B, Vandamme AM, Van Weyenbergh J. Ascorbic acid has superior ex vivo anti-proliferative, cell death-inducing and immunomodulatory effects over IFN- α in HTLV-1-associated myelopathy. *PLoS Negl Trop Dis.* 2012;6(7): e1729.
- Menezes SM, Decanine D, Brassat D, Khouri R, Schnitman SV, Kruschewsky R, López G, Alvarez C, Talledo M, Gotuzzo E, Vandamme AM, Galvão-Castro B, Liblau R, Weyenbergh JV. CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis. *J Neuroinflammation.* 2014;29(11):18.
- Leal FE, Menezes SM, Costa EAS, Brailey PM, Gama L, Segurado AC, Kallas EG, Nixon DF, Dierckx T, Khouri R, Vercauteren J, Galvão-Castro B, Saraiva Raposo RA, Van Weyenbergh J. Comprehensive antiretroviral restriction factor profiling reveals the evolutionary imprint of the ex vivo and in vivo IFN- β response in HTLV-1-associated neuroinflammation. *Front Microbiol.* 2018;22(9):985.
- Khouri R, Silva-Santos G, Dierckx T, Menezes SM, Decanine D, Theys K, et al. A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and apoptosis in healthy controls and Adult T-cell Leukemia patients. *Oncoimmunology.* 2018;7: e1426423.
- Kagdi H, Demontis MA, Ramos JC, Taylor GP. Switching and loss of cellular cytokine producing capacity characterize in vivo viral infection and malignant transformation in human T-lymphotropic virus type 1 infection. *PLoS Pathog.* 2018. <https://doi.org/10.1371/journal.ppat.1006861>.
- Chen Y, Zhu J, Lum PY, Yang X, Pinto S, Macneil DJ, Zhang C, Lamb J, Edwards S, Sieberts SK, Leonardson A, Castellini LW, Wang S, Champy MF, Zhang B, Emilsson V, Doss S, Ghazalpour A, Horvath S, Drake TA, Lusis AJ, Schadt EE. Variations in DNA elucidate molecular networks that cause disease. *Nature.* 2008;452:429–35.
- Zhang B, Gaiteri C, Bodea LG, Wang Z, Mcelwee J, Podtelezchnikov AA, Zhang C, Xie T, Tran L, Dobrin R, Fluder E, Clurman B, Melquist S, Narayanan M, Suver C, Shah H, Mahajan M, Gillis T, Mysore J, Macdonald ME, Lamb JR, Bennett DA, Molony C, Stone DJ, Gudnason V, Myers AJ, Schadt EE, Neumann H, Zhu J, Emilsson V. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell.* 2013;153:707–20.

31. Meng Q, Zhuang Y, Ying Z, Agrawal R, Yang X, Gomez-Pinilla F. Traumatic brain injury induces genome-wide transcriptomic, methylomic, and network perturbations in brain and blood predicting neurological disorders. *EBioMedicine*. 2017;16:184–94. <https://doi.org/10.1016/j.ebiom.2017.01.046>.
32. Tattermusch S, Skinner JA, Chaussabel D, Banchereau J, Berry MP, McNab FW, et al. Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy. *PLoS Pathog*. 2012;8:e1002480.
33. Yamauchi J, Tanabe K, Sato T, Nakagawa M, Matsuura E, Tsuboi Y, Tamaki K, Sakima H, Ishihara S, Ohta Y, Matsumoto N, Kono K, Yagishita N, Araya N, Takahashi K, Kunitomo Y, Nagasaka M, Coler-Reilly A, Hasegawa Y, Araujo A, Jacobson S, Grassi MFR, Galvão-Castro B, Bland M, Taylor GP, Martin F, Yamano Y. Efficacy of corticosteroid therapy for HTLV-1-associated myelopathy: a randomized controlled trial (HAMLET-P). *Viruses*. 2022;14(1):136.
34. Adriaensen W, Matheï C, Vaes B, van Pottelbergh G, Wallemacq P, Degryse J-M. Interleukin-6 as a first-rated serum inflammatory marker to predict mortality and hospitalization in the oldest old: a regression and CART approach in the BELFRAIL study. *Exp Gerontol*. 2015;69:53–61.
35. Marcos-Pérez D, Sánchez-Flores M, Proietti S, Bonassi S, Costa S, Teixeira JP, et al. Association of inflammatory mediators with frailty status in older adults: results from a systematic review and meta-analysis. *GeroScience*. 2020;42:1451–73.
36. Schierhout G, McGregor S, Gessain A, Einsiedel L, Martinello M, Kaldor J. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. *Lancet Infect Dis*. 2020;20(1):133–43.
37. Mühl H. Pro-inflammatory signaling by IL-10 and IL-22: bad habit stirred up by interferons? *Front Immunol*. 2013;4(4):18.
38. McElvaney OJ, Hobbs BD, Qiao D, McElvaney OF, Moll M, McEvoy NL, Clarke J, O'Connor E, Walsh S, Cho MH, Curley GF, McElvaney NG. A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. *EBioMedicine*. 2020;61: 103026.
39. Ghosh N, Saha I, Sharma N. Interactome of human and SARS-CoV-2 proteins to identify human hub proteins associated with comorbidities. *Comput Biol Med*. 2021;138: 104889.
40. Galvão-Castro B, Rios Grassi MF, Nunes A, Galvão-Barroso AK, Galvão-Castro AV, Lírio M, Ribeiro A, de Faria JT, Silva AL, Cerqueira M, Rangel SL, Araujo THA, Boa-Sorte N, Dourado I, Castro-Lima H, Soliani MLC. Challenges in establishing telehealth care during the COVID-19 pandemic in a neglected HTLV-1-infected population in northeastern Brazil. *PLoS Negl Trop Dis*. 2020;14(12): e0008922.
41. Yamano Y, Araya N, Sato T, Utsunomiya A, Azakami K, Hasegawa D, et al. Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. *PLoS ONE*. 2009;4: e6517.
42. Starling AL, Coelho-Dos-Reis JG, Peruhype-Magalhães V, Pascoal-Xavier MA, Gonçalves DU, Béla SR, Lambertucci JR, Labanca L, Souza Pereira SR, Teixeira-Carvalho A, Ribas JG, Trindade BC, Faccioli LH, Carneiro-Proietti AB, Martins-Filho OA. Immunological signature of the different clinical stages of the HTLV-1 infection: establishing serum biomarkers for HTLV-1-associated disease morbidity. *Biomarkers*. 2015;20(6–7):502–12.
43. Ando H, Sato T, Tomaru U, Yoshida M, Utsunomiya A, Yamauchi J, Araya N, Yagishita N, Coler-Reilly A, Shimizu Y, Yudoh K, Hasegawa Y, Nishioka K, Nakajima T, Jacobson S, Yamano Y. Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy. *Brain*. 2013;136(Pt 9):2876–87.24.
44. Furuya T, Nakamura T, Fujimoto T, Nakane S, Kambara C, Shirabe S, Hamasaki S, Motomura M, Eguchi K. Elevated levels of interleukin-12 and interferon-gamma in patients with human T lymphotropic virus type I-associated myelopathy. *J Neuroimmunol*. 1999;95(1–2):185–9.
45. Montanheiro PA, Penalva de Oliveira AC, Smid J, Fukumori LM, Olah I, S Duarte SAJ, Casseb J. The elevated interferon gamma production is an important immunological marker in HAM/TSP pathogenesis. *Scand J Immunol*. 2009;70(4):403–7.
46. Leal FE, Ndhlovu LC, Hasenkrug AM, Bruno FR, Carvalho KI, Wynn-Williams H, Neto WK, Sanabani SS, Segurado AC, Nixon DF, Kallas EG. Expansion in CD39+ CD4+ immunoregulatory t cells and rarity of Th17 cells in HTLV-1 infected patients is associated with neurological complications. *PLoS Negl Trop Dis*. 2013;7(2): e2028.
47. Romanelli LCF, Miranda DM, Carneiro-Proietti ABF, Mamede M, Vasconcelos HMM, Martins ML, Ferreira ASD, Rosa DVF, Paula JJ, Romano-Silva MA, Nicolato R. Spinal cord hypometabolism associated with infection by human T-cell lymphotropic virus type 1 (HTLV-1). *PLoS Negl Trop Dis*. 2018;12(8): e0006720.
48. Santos SB, Oliveira P, Luna T, Souza A, Nascimento M, Siqueira I, Tanajura D, Muniz AL, Glesby MJ, Carvalho EM. Immunological and viral features in patients with overactive bladder associated with human T-cell lymphotropic virus type 1 infection. *J Med Virol*. 2012;84(11):1809–17.
49. Romanelli LC, Caramelli P, Martins ML, Gonçalves DU, Proietti FA, Ribas JG, Araújo MG, Carneiro-Proietti AB. Incidence of human T cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in a long-term prospective cohort study of initially asymptomatic individuals in Brazil. *AIDS Res Hum Retroviruses*. 2013;29(9):1199–202.
50. Tanajura D, Castro N, Oliveira P, Neto A, Muniz A, Carvalho NB, Orge G, Santos S, Glesby MJ, Carvalho EM. Neurological manifestations in human T-cell lymphotropic virus type 1 (HTLV-1)-infected individuals without HTLV-1-associated myelopathy/tropical spastic paraparesis: a longitudinal cohort study. *Clin Infect Dis*. 2015;61(1):49–56.
51. Ferraz SN, Costa GF, Carneiro Neto JA, Hebert T, de Oliveira CJV, Guerra M, Oliveira LMA, Carvalho EM. Neurologic, clinical, and immunologic features in a cohort of HTLV-1 carriers with high proviral loads. *J Neurovirol*. 2020;26(4):520–9.
52. Martins ML, Guimarães JC, Ribas JG, Romanelli LC, de Freitas Carneiro-Proietti AB. Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM/TSP: what is its relevance as a prognostic marker for neurologic disease? *J Neurovirol*. 2017;23(1):125–33.
53. Sato T, Coler-Reilly A, Utsunomiya A, Araya N, Yagishita N, Ando H, et al. CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis. *PLoS Negl Trop Dis*. 2013;7: e2479.
54. Sato T, Yagishita N, Tamaki K, Inoue E, Hasegawa D, Nagasaka M, et al. Proposal of classification criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis disease activity. *Front Microbiol*. 2018;9:1651.
55. Tamaki K, Sato T, Tsugawa J, Fujioka S, Yagishita N, Araya N, et al. Cerebrospinal fluid CXCL10 as a candidate surrogate marker for HTLV-1-associated myelopathy/tropical spastic paraparesis. *Front Microbiol*. 2019;10:2110.
56. Rosadas C, Zetterberg H, Heslegrave A, Haddow J, Borisova M, Taylor GP. Neurofilament light in CSF and plasma is a marker of neuronal damage in HTLV-1-associated myelopathy and correlates with neuroinflammation. *Neurol Neuroimmunol Neuroinflamm*. 2021;8(6): e1090.
57. Souza FDS, Freitas NL, Gomes YCP, Torres RC, Echevarria-Lima J, da Silva-Filho IL, Leite ACCB, de Lima MASD, da Silva MTT, Araújo AQC, Espindola OM. Following the clues: usefulness of biomarkers of neuroinflammation and neurodegeneration in the investigation of HTLV-1-associated myelopathy progression. *Front Immunol*. 2021;12: 737941.
58. Gomes YCP, Freitas NL, Souza FS, Sandim V, Pereira DA, Nogueira FCS, Echevarria-Lima J, Leite ACCB, Lima MASD, Silva MTT, Araújo AQC, Vicente ACP, Espindola OM. Chitotriosidase 1 in the cerebrospinal fluid as a putative biomarker for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) progression. *Front Immunol*. 2022;16(13): 949516.
59. Vasunilashorn SM, Ngo LH, Dillon ST, et al. Plasma and cerebrospinal fluid inflammation and the blood-brain barrier in older surgical patients: the Role of Inflammation after Surgery for Elders (RISE) study. *J Neuroinflammation*. 2021;18:103.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.